Thanks for the input, Neuro. We seem to be trapped in a fog (maybe a different version of the trapped longs Jerry referred to a while back).
Hard to gauge the impact of the law suits in France. I agree they could be negatively impacting Servier's R+D strategy.
Here it seems to be, unfortunately, part of routine pharmaceutical business. J&J will be appealing their 1.1B Risperdal judgement and I think some of their executives are still at risk with the Tylenol shenanigans. Most of the BP's here, have had significant suits. Looks like the contagion is spreading to Europe. New drugs need to be squeaky clean, otherwise they will be sucked into the quagmire.
Who could have forseen that Risperdal would be found faulty, based on weight gain-->diabetes-->vascular disease after longterm use. Perhaps, the lawyers should sue the USDA, instead, or whoever created the food pyramid, fueling obesity, because the carbohydrates and grains at the base might need to be more restricted than fats and protein at the apex of the pyramid.